Oral anticoagulant treatment in geriatric patients with nonvalvular atrial fibrillation in the era of direct oral anticoagulant agents

2014 ◽  
Vol 25 (5) ◽  
pp. e63-e65 ◽  
Author(s):  
Marjorie Kayser ◽  
Yves Frances ◽  
Laurent Bonello ◽  
Franck Paganelli ◽  
Michael Peyrol
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulant ◽  
Geriatric Patients ◽  
Direct Oral Anticoagulant ◽  
Anticoagulant Treatment ◽  
Nonvalvular Atrial Fibrillation ◽  
Oral Anticoagulant Treatment ◽  
Anticoagulant Agents

scholarly journals The Risk/Benefit Analysis of Oral Anticoagulant Treatment in Atrial Fibrillation Using HAS-BLED and CHA2DS2-VASc Score

2015 ◽  
Vol 61 (4) ◽  
pp. 269-272
Author(s):  
Silivastru (Cozlea) Ionela ◽  
Cozlea Daniel Laurentiu ◽  
Keresztesi Arthur Attila ◽  
Asofie Gabriela ◽  
Cozlea Laurentiu ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulant ◽  
Thromboembolic Events ◽  
Anticoagulant Treatment ◽  
Bleeding Events ◽  
Nonvalvular Atrial Fibrillation ◽  
Oral Anticoagulant Treatment ◽  
Risk Class ◽  
Number Of Patients ◽  
History Of

AbstractIntroduction. The purpose of this study is to evaluate the risk and the benefit of oral anticoagulant treatment in nonvalvular atrial fibrillation (AF) patients, using the two scores recommended by the guidelines: the CHA2DS2-VASc score and HAS-BLED score.Material and method. We conducted a retrospective observational study on 144 patients with nonvalvular atrial fibrillation, admitted between 1st of July 2013 and 30th September 2013 in the 3rd Medical Clinic of Tîrgu Mureș with a prospectiv follow-up at 6 months.Based on the data collected from the patient charts, the thromboembolic risk was assessed using the CHA2DS2-VASc score and the hemorrhage risk was assessed using the HAS-BLED score. At 6 months, the patients were contacted via telephone and were questioned regarding their state of health, the existence of hospitalizations in the last 6 months, the international normalized ratio (INR) value, the existence of hemorrhagic or thromboembolic events.Results. The group of patients was composed of 70 female and 74 male with the mean age of 70 ±11 years. From the total number of patients 13 (11.7%) had a history of stroke and the CHA2DS2-VASc score revealed that these 13 were in the high risk class. The presence of arterial hypertension and vascular disease were statistically associated with stroke.Hemorrhagic events were encountered in 19 patients (13.19%) and 16 of them had a higher than 3 HAS-BLED score. A history of bleeding, anemia and labile INR were the factors statistically associated with bleeding.Conclusions. The CHA2DS2-VASc score is useful in stratifying patients with AF in risk groups for thromboembolic events while the HAS-BLED score proved to be a useful tool in predicting bleeding events in anticoagulated patients.

Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF study

2015 ◽  
Vol 215 (2) ◽  
pp. 73-82
Author(s):  
F. de Andrés-Nogales ◽  
I. Oyagüez ◽  
L. Betegón-Nicolás ◽  
C. Canal-Fontcuberta ◽  
J. Soto-Álvarez
Keyword(s):  
Atrial Fibrillation ◽  
Oral Anticoagulant ◽  
Anticoagulant Treatment ◽  
Nonvalvular Atrial Fibrillation ◽  
Oral Anticoagulant Treatment

Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin

2019 ◽  
Vol 76 (5) ◽  
pp. 275-285 ◽  
Author(s):  
Manasi Datar ◽  
Concetta Crivera ◽  
Heather Rozjabek ◽  
Ibrahim M Abbass ◽  
Yihua Xu ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Real World ◽  
Oral Anticoagulant ◽  
Direct Oral Anticoagulant ◽  
Nonvalvular Atrial Fibrillation ◽  
Anticoagulant Agents

“Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation

2016 ◽  
Vol 116 (10) ◽  
pp. 587-589 ◽  
Author(s):  
Gregory Y. H. Lip ◽  
Ben Freedman
Keyword(s):  
Atrial Fibrillation ◽  
Real World ◽  
Oral Anticoagulant ◽  
Review Process ◽  
Anticoagulant Treatment ◽  
Real World Data ◽  
Oral Anticoagulant Treatment ◽  
World Data

Note: The review process for this manuscript was fully handled by Christian Weber, Editor in Chief.

scholarly journals Laboratory tests during direct oral anticoagulant treatment? No

2013 ◽  
Vol 8 (5) ◽  
pp. 367-370 ◽  
Author(s):  
Giovanni Di Minno ◽  
Elena Ricciardi ◽  
Antonella Scalera
Keyword(s):  
Oral Anticoagulant ◽  
Laboratory Tests ◽  
Direct Oral Anticoagulant ◽  
Anticoagulant Treatment ◽  
Oral Anticoagulant Treatment

P4745Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
J J Komen ◽  
P Hjemdahl ◽  
A K Mantel - Teeuwisse ◽  
O H Klungel ◽  
B Wettermark ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Propensity Score ◽  
Oral Anticoagulant ◽  
Cox Regression ◽  
Oral Anticoagulants ◽  
Anticoagulant Treatment ◽  
Oral Anticoagulant Treatment ◽  
Increased Risk ◽  
Antidepressant Use

Abstract Background Anticoagulation treatment reduces the risk of stroke but increases the risk of bleeding in atrial fibrillation (AF) patients. Antidepressants use is associated with increased risk for stroke and bleeds. Objective To assess the association between antidepressant use in AF patients with oral anticoagulants and bleeding and stroke risk. Methods All AF patients newly prescribed with an oral anticoagulant in the Stockholm Healthcare database (n=2.3 million inhabitants) from July 2011 until 2016 were included and followed for one year or shorter if they stopped claiming oral anticoagulant treatment or had an outcome of interest. Outcomes were severe bleeds and strokes, requiring acute hospital care. During follow-up, patients were considered exposed to antidepressant after claiming a prescription for the duration of the prescription. With a time-varying Cox regression, we assessed the association between antidepressant use and strokes and bleeds, adjusting for confounders (i.e., age, sex, comorbidities, comedication, and year of inclusion). In addition, we performed a propensity score matched analysis to test the robustness of our findings. Results Of the 30,595 patients included after claiming a prescription for a NOAC (n=13,506) or warfarin (n=17,089), 4 303 claimed a prescription for an antidepressant during follow-up. A total of 712 severe bleeds and 551 strokes were recorded in the cohort. Concomitant oral anticoagulant and antidepressant use was associated with increased rates of severe bleeds (4.7 vs 2.7 per 100 person-years) compared to oral anticoagulant treatment without antidepressant use (aHR 1.42, 95% CI: 1.12–1.80), but not significantly associated with increased stroke rates (3.5 vs 2.1 per 100 person-years, aHR 1.23, 95% CI: 0.93–1.62). No significant differences were observed between different oral anticoagulant classes (i.e., warfarin or NOAC) or different antidepressant classes (i.e., SSRI, TCA, or other antidepressant). Additional propensity-score matched analyses yielded similar results but showed a significantly increased risk for stroke (HR: 1.47, 95% CI: 1.08–2.02). Incidence rates of strokes and bleeds Conclusion Concomitant use of an oral anticoagulant and an antidepressant, irrespective of type, is associated with an increased bleeding risk. Increased awareness and a critical consideration for the need of an antidepressant is recommended in this population. Acknowledgement/Funding Swedish Heart Lung Foundation

Sign in / Sign up

Export Citation Format

Share Document